Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 10/20 | 0.40 |
| ▸ | MME | P08473 | 10/20 | 0.40 |
| ▸ | CPA1 | P15085 | 9/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071712 | 0.86 | HDAC3 (0.44) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL22290251 | 0.86 | HDAC3 (0.44) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL1070368 | 0.83 | ACE (0.49) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL1070367 | 0.83 | ACE (0.49) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL25471841 | 0.82 | ALOX15 (0.41) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL1070147 | 0.82 | FPR2 (0.49) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL25265326 | 0.82 | FPR2 (0.49) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL1070178 | 0.82 | FPR2 (0.49) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL25192552 | 0.82 | FPR2 (0.49) | ALOX15ACEMMECPA1ACE2 | |
| SCHEMBL1070175 | 0.82 | FPR2 (0.49) | ALOX15ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-30 | — | — | US | disclosed |
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| EP-3917504-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | Arizona Board of Regents on behalf of the University of Arizona (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160256-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| US-9173862-B2 | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | Arizona Board of Regents, a body Corporate of the State of Arizona, acting for and on behalf of the (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2273988-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009129497-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS, A BODY CORP. OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-22 | — | — | WO | disclosed |
| US-4065566-A | PRO-DRUG FORM OF L-DOPA, PARKINSON*S DISEASE | INTERX RESEARCH CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | MTNR1A, MC1R, MTNR1B | ALOX15 674/4885ACE 3477/4885MME 823/4885 |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | MTNR1A, MC1R, MTNR1B | ALOX15 674/4885ACE 3477/4885MME 823/4885 |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | PDE6C, AGER, PDE6D | ALOX15 118/4885ACE 1091/4885MME 494/4885 |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | PDE6C, PDE6D, AGER | ALOX15 164/4885ACE 1287/4885MME 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.